Protein-based therapeutics are at the forefront of biomedical research, and have been used to treat a variety of conditions with unmet medical needs. Biologics such as therapeutic antibodies have transformed the field of oncology and led to transformative cancer immunotherapy treatments.
At the same time, the increase in genomic sequencing, proteomic data, real world evidence, and electronic health records have led to a wealth of available information which can be leveraged to extract relevant pharmaceutical insights. Cutting-edge artificial intelligence algorithms in computer vision, natural language processing, and generative machine learning have matured and can be brought to bear on these curated datasets to enable data-driven decision making in pharmaceutical R&D problems.
AINovo™ Biotech Inc. is leveraging this unique interdisciplinary opportunity afforded by massively growing biomedical datasets, modern machine learning algorithms, and growing unmet medical needs in order to accomplish our mission of enabling data-driven discovery of novel biologic therapeutics and diagnostics for patients.
New Generation Biologics. Designed and Optimized with AI.
Data-driven biologics design and optimization. Meet our biological data engine (AICurius™), protein design engine (AIGenus™), and biologics optimization engine (AIOptimus™).
Our Focus Areas
We develop transformative therapeutics across multiple disease areas through joint-development partnerships as well as internal development programs.
Antibiotic resistance is the most insidious public health challenge of our time. AINovo discovers novel therapeutics to alleviate the burden of antibiotic-resistance and battle emerging pathogenic threats.
AINovo is pioneering new therapeutic modalities based on our Novobinder Platform to harness the power of the human immune system to directly attack cancer cells
AINovo is applying our Novobinder™ technology to better understand the processes of pathogenesis and to drive improved outcomes in precision medicine.